{'fraction_non_alphanumeric': 0.0288135593220339, 'fraction_numerical': 0.010169491525423728, 'mean_word_length': 6.035714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Complex intensive treatment shows promise against a complex aggressive disease

Neuromyelitis optica (NMO) spectrum disorder (NMOSD) comprises a group of neuroinflammatory disorders characteristically affecting the optic nerves and the spinal cord. Previously known as Devic disease, NMO was considered a variant of multiple sclerosis (MS) until the discovery of anti-aquaporin 4 immunoglobulin G (AQP4-IgG) identified NMO as a separate disease.1 Over the following decade, studies of NMOSD have described with increasing precision the clinical,2 radiologic,3 and neuropathologic4 features.